Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured

Published in Advanced Melanoma and

Expert Opinion / Commentary · December 19, 2019

2019 Top Stories in Oncology: Stage IV Melanoma: Overall Survival Improvement With Modern Therapy

Written by

Roxana S. Dronca MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

References

Notice to Our Valued Users

Advanced Melanoma

2019 Top Stories in Oncology: Stage IV Melanoma: Overall Survival Improvement With Modern Therapy

Additional Info

Further Reading

Response to Checkpoint Inhibition and Targeted Therapy in Patients With Melanoma With Concurrent Haematological Malignancies

Utility of MIA and MSKCC Nomograms in Selecting Patients With Melanoma for Sentinel Lymph Node Biopsy

Adjuvant Systemic Therapy or Watchful Waiting in Patient With Multiple Comorbidities?

Progression of Disease in a Patient With Previous irAE on Ipi+Nivo; What's Next?

IFN-γ Signature Enables the Selection of Neoadjuvant Treatment in Patients With Stage III Melanoma

Young Patient With Li-Fraumeni Syndrome With Melanoma Metastasis of Unknown Primary

ctDNA-Based Molecular Residual Disease Detection for Treatment Monitoring in Patients With Advanced Melanoma

Decision-Making and HRQoL in Patients With Melanoma Considering Adjuvant Immunotherapy

Recurrence of Disease During Fertility Procedures; Patient Tailored Treatment?

Neoadjuvant–Adjuvant vs Adjuvant-Only Pembrolizumab for Advanced Melanoma

Alternatives and a Reduced Need for Sentinel Lymph Node Biopsy Staging for Melanoma

Recently Updated